[go: up one dir, main page]

CL2022001353A1 - Inhibidores de egfr - Google Patents

Inhibidores de egfr

Info

Publication number
CL2022001353A1
CL2022001353A1 CL2022001353A CL2022001353A CL2022001353A1 CL 2022001353 A1 CL2022001353 A1 CL 2022001353A1 CL 2022001353 A CL2022001353 A CL 2022001353A CL 2022001353 A CL2022001353 A CL 2022001353A CL 2022001353 A1 CL2022001353 A1 CL 2022001353A1
Authority
CL
Chile
Prior art keywords
compound
egfr inhibitors
formula
medicament
pharmaceutically acceptable
Prior art date
Application number
CL2022001353A
Other languages
English (en)
Inventor
Jaeschke Georg
Kuhn Bernd
Alice Nagel Yvonne
Ricci Antonio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2022001353A1 publication Critical patent/CL2022001353A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud proporciona un compuesto que tiene la Fórmula general (I), o una sal farmacéuticamente aceptable de este, composiciones que incluyen el compuesto y métodos de uso del compuesto. El compuesto de Fórmula (I) se puede usar como un medicamento.
CL2022001353A 2019-12-20 2022-05-24 Inhibidores de egfr CL2022001353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19218403 2019-12-20

Publications (1)

Publication Number Publication Date
CL2022001353A1 true CL2022001353A1 (es) 2023-02-17

Family

ID=69411052

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001353A CL2022001353A1 (es) 2019-12-20 2022-05-24 Inhibidores de egfr

Country Status (18)

Country Link
US (1) US20230034696A1 (es)
EP (1) EP4076664B1 (es)
JP (1) JP7737991B2 (es)
KR (1) KR20220118426A (es)
CN (1) CN114867531B (es)
AR (1) AR120799A1 (es)
AU (1) AU2020405326A1 (es)
BR (1) BR112022011690A2 (es)
CA (1) CA3160534A1 (es)
CL (1) CL2022001353A1 (es)
CO (1) CO2022006965A2 (es)
CR (1) CR20220255A (es)
IL (1) IL292104A (es)
MX (1) MX2022007634A (es)
PE (1) PE20221768A1 (es)
PH (1) PH12022551241A1 (es)
TW (1) TW202136263A (es)
WO (1) WO2021123084A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441704B2 (en) 2019-12-20 2025-10-14 Nuevolution A/S Compounds active towards nuclear receptors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025445B1 (pt) 2019-06-21 2024-02-27 F. Hoffmann-La Roche Ag Composto, composição farmacêutica e usos de um composto
AU2020383423A1 (en) 2019-11-11 2022-06-23 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
CN115135315B (zh) 2019-12-20 2024-11-26 米拉蒂治疗股份有限公司 Sos1抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
US10385019B2 (en) * 2015-06-30 2019-08-20 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
GB201519644D0 (en) * 2015-11-06 2015-12-23 Univ Southampton Therapy and pharmaceutical composition
EP3528798A4 (en) * 2016-10-19 2020-10-21 United States Government as Represented by The Department of Veterans Affairs COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
TW201945357A (zh) 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2019183523A1 (en) * 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
MA53003A (fr) * 2018-06-29 2021-05-05 Hoffmann La Roche Composés

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441704B2 (en) 2019-12-20 2025-10-14 Nuevolution A/S Compounds active towards nuclear receptors

Also Published As

Publication number Publication date
TW202136263A (zh) 2021-10-01
IL292104A (en) 2022-06-01
EP4076664A1 (en) 2022-10-26
AR120799A1 (es) 2022-03-16
PH12022551241A1 (en) 2023-10-09
BR112022011690A2 (pt) 2022-09-06
AU2020405326A1 (en) 2022-05-12
JP7737991B2 (ja) 2025-09-11
KR20220118426A (ko) 2022-08-25
MX2022007634A (es) 2022-07-19
CA3160534A1 (en) 2021-06-24
CN114867531A (zh) 2022-08-05
PE20221768A1 (es) 2022-11-11
WO2021123084A1 (en) 2021-06-24
JP2023506809A (ja) 2023-02-20
US20230034696A1 (en) 2023-02-02
EP4076664B1 (en) 2023-08-30
CR20220255A (es) 2022-07-11
EP4076664C0 (en) 2023-08-30
CN114867531B (zh) 2024-03-22
CO2022006965A2 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
CL2022001353A1 (es) Inhibidores de egfr
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
JOP20220008A1 (ar) مثبطات parp1
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
EA202193015A1 (ru) Ингибиторы cdk
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
UY38358A (es) Inhibidores de sarcómeros cardíacos
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CL2022001492A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
AR077629A1 (es) Mimetico de smac
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2020004694A (es) Composiciones farmaceuticas inyectables de isoxazolina y su uso contra la infestacion de parasitos.
CL2022000725A1 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CO2022000270A2 (es) Inhibidores de enzimas
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas